ASPI - Form 8-k current report
ASPI has completed its acquisition of Renergen on January 6, 2026, through a scheme of arrangement. Renergen shareholders received 0.09196 shares of ASPI for each Renergen share, resulting in the issuance of 14 270 000 consideration shares. Renergen is now a wholly owned subsidiary of ASPI, and its shares will be delisted from the JSE, Australian Securities Exchange, and A2X. The transaction maintains ASPI’s listing on Nasdaq and the JSE. Renergen’s CEO and COO have been appointed to key roles within ASPI. The completion was announced via a press release on January 7, 2026.
|
